Methods to increase or decrease bone density

Details Methods to increase or decrease bone density Methods to increase or decrease bone density

2007-12-19

2010-02-02

Saoud, Christine J (Department: 1647)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S375000, C436S501000, C514S218000

Reexamination Certificate

active

07655420

ABSTRACT:
The SOST gene gives rise to sclerostin, a protein that leads to apoptosis of bone progenitor cells. The invention provides antagonists to the sclerostin protein, and methods for identifying new sclerostin antagonists. The invention also provides molecules that can depress expression of the SOST gene, as well as methods for identifying such molecules. Such molecules and antagonists are useful for increasing bone mineralization in mammals, for example, in the treatment of osteoporosis.

REFERENCES:
patent: 3561444 (1971-02-01), Boucher
patent: 3703173 (1972-11-01), Dixon
patent: 4036945 (1977-07-01), Haber
patent: 4051842 (1977-10-01), Hazel et al.
patent: 4140122 (1979-02-01), Kuhl et al.
patent: 4331647 (1982-05-01), Goldenberg
patent: 4383529 (1983-05-01), Webster
patent: 4624251 (1986-11-01), Miller
patent: 4635627 (1987-01-01), Gam
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4960432 (1990-10-01), Junino et al.
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 5073174 (1991-12-01), Vayssie et al.
patent: 5382587 (1995-01-01), Baldwin et al.
patent: 5622856 (1997-04-01), Natsoulis
patent: 5658776 (1997-08-01), Flotte et al.
patent: 5658785 (1997-08-01), Johnson
patent: 5837484 (1998-11-01), Trempe et al.
patent: 5980584 (1999-11-01), Lim et al.
patent: 6258595 (2001-07-01), Gao et al.
patent: 6342079 (2002-01-01), Pan et al.
patent: 6365403 (2002-04-01), Natsoulis et al.
patent: 6395511 (2002-05-01), Brunkow et al.
patent: 6475769 (2002-11-01), Wilson et al.
patent: 6489445 (2002-12-01), Brunkow et al.
patent: 6541258 (2003-04-01), Allen et al.
patent: 2003/0186915 (2003-10-01), Pan et al.
patent: 3441148 (1986-05-01), None
patent: 20013155 (2000-10-01), None
patent: 0182187 (1986-05-01), None
patent: 404097 (1990-12-01), None
patent: WO-93/11161 (1993-06-01), None
patent: WO-94/07529 (1994-04-01), None
patent: WO-99/41399 (1999-08-01), None
Abe et al., “Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin,”J. Bone. Min. Res.15(4): 663-73 (2000).
Aitken et al., “A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease,”Hum. Gene Ther.12: 1907-16 (2001).
Arenz et al., “Synthesis of the First Selective Irreversible Inhibitor of Neutral Sphingomyelinase,”Angewandte Chemie Intl. Ed., 39(8): 1440-2 (2000).
Balemans et al., “Extracellular regulation of BMP signaling in vertebrates: A cocktail of modulators,”Dev. Biol.250: 231-50 (2002).
Barnes et al., “Purification of Immunoglobulin G (IgG); Methods in Molecular Biology,” Humana Press, 10: 79-104 (1992).
Beighton et al., “The clinical features of sclerosteosis, A review of the manifestations in twenty-five affected individuals,”Ann. Int. Med.84:393-7 (1976).
Beresford et al., “Marrow Stromal Cell Culture,” Cambridge University Press.
Bird et al., “Single-chain antigen-binding proteins,”Science.242(4877): 423-6 (1988).
Boden et al., “Glucocorticoid-induced differentiation of fetal rat calvarial osteoblasts is mediated by bone morphogenetic protein-6,”Endocrinol.138: 2820-8 (1997).
Bostrom et al., “Immunolocalization and expression of bone morphogenetic proteins 2 and 4 in fracture healing,”J. Orthopaedic Res.13: 357-67 (1995).
Brunkow et al., “Bone dysplasia scleroteosis results from loss of the SOST gene product, a novel cystine knot-containing protein,”Am. J. Hum. Genet.68: 577-89 (2001).
Budd et al., “Death receptors couple to both cell proliferation and apoptosis,”J. Clin. Invest.109(4): 437-41 (2002).
Carter et al., “AAV vectors for gene therapy. Gene and Cell Therapy: Therapeutic Mechanisms and Strategies,” 2ndEdition, Marcel Dekker, New York: 71-101 (2004).
Clackson et al., “Making antibody fragments using phage display libraries,”Nature.352(6336): 624-8 (1991).
Clark et al., “Cell lines for the production of recombinant adeno-associated virus,”Hum. Gene Ther.9: 1329-41 (1995).
Clark et al., “A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors”,Gene Therapy3:1124-1132 (1996).
Clark et al., “Highly Purified Recombinant Adeno-Associated Virus Vectors Are Biologically Active and Free of Detectable Helper and Wild-Type Viruses”,Hum Gene Therapy10(6):1031-1039 (1999).
Clark et al., “Recombinant Adeno-Associated Viral Vectors Mediate Long-Term Transgene Expression in Muscle”,Hum Gene Therapy8(6):659-669 (1997).
Clothia et al., “Domain association in immunoglobulin molecules. The packing of variable domains.,”J. Mol. Biol.186(3): 651-63 (1985).
Coligan et al., “Current Protocols in Immunology,” Wiley Interscience, Unit 9 (1991).
Coligan et al., “Production of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters. Current Protocols in Immunology,” Section 2.5.1-2.6.7 (1992).
Coligan et al., “Production of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters. Current Protocols in Immunology,” Section 2.7.1-2.7.12 (1992).
Coligan et al., “Production of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters. Current Protocols in Immunology,” Section 2.9.1-2.9.3 (1992).
Coligan et al., “Production of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters. Current Protocols in Immunology,” Section 2.4.1 (1992).
Cooper et al., “Glucocorticoid activity, inactivity and the osteoblast,”J. Endocrinology.163(2): 159-64 (1999).
Epstein et al., “Endocrine function in sclerosteosis,”S. Afr. Med. J.55: 1105-10 (1979).
Fan and Dong, “Replication of rep-cap Genes Is Essential for the High-Efficiency Production of Recombinant AAV”,Human Gene Therapy8:87-98 (1997).
Fang et al., “Stimulation of new bone formation by direct transfer of osteogenic plasmid genes,”Proc. Natl. Acad. Sci. USA. 93: 5753 (1996).
Gao et al., “Rep/Cap Gene Amplification and High-Yield Production of AAV in an A549 Cell Line Expressing Rep/Cap”,Molecular Therapy5(5):644-649 (2002).
Gazit et al., “Modulation of expression and cell surface binding of members of the transforming growth factor-beta superfamily during retinoic acid-induced osteoblastic differentiation of multipotential mesenchymal cells ,”Mol. Endocrinol.7(2): 189-98 (1993).
Gazzerro et al., “Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts,”J. Clin. Invest.102: 2106-14 ( ).
Gitelman et al., “Vgr-1/BMP-6 induces osteoblastic differentiation of pluripotential mesenchymal cells,”Cell Growth and Differ.6(7): 827-36 (1995).
Graham and Prevec, “Methods for Construction of Adenovirus Vectors”,Mol. Biotechnol.3:207-220 (1995).
Green et al., “Production of Polyclonal Antisera. Immunochemical Protocols,”Humana Press, 1-5.
Handbook of Parvoviruses, vol. I (P. Tjissen, ed.) CRC Press, Boca Raton, pp. 255-282 (1989).
Harlow et al., “Antibodies: A Laboratory Manual. Cold Spring Harbor Publishers, Cold Spring Harbor,” New York: (1988).
Hill et al., “Multiple extracellular signals promote osteoblast survival and apoptosis,”Endocrinology.138: 3849-58 (1997).
Hock et al., “Perspective, osteoblast apoptosis and bone turnover,”J. Bone Miner. Res.16: 975-84 (2001).
Hofmann et al., “Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription,”FEBS Letters. 441(3): 441-6 (1998).
Holliger et al., “‘Diabodies’: Small bivalent and bispecific antibody fragments.”Proc. Natl. Acad. Sci. USA. 90: 6444-8 (1993).
Holmes et al., “Structural consequences of humanizing an

Affiliated with

Also associated with

Rating

Methods to increase or decrease bone density does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods to increase or decrease bone density, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to increase or decrease bone density will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4176186